5 min read

FAILURE MODE EFFECT ANALYSIS FOR BLISTER PACKING MACHINE

August 2, 2026

FAILURE MODE EFFECT ANALYSIS REPORT FOR BLISTER PACKING MACHINE

INTRODUCTION:

According to Annex 15 of the EU-GMP Guide, Risk Assessment is a systematic process used to identify, analyze, evaluate, control and review potential risks associated with equipment, utilities, systems and manufacturing processes that may affect product quality, patient safety, data integrity and regulatory compliance.

Failure Mode and Effects Analysis (FMEA) is one of the most widely accepted Quality Risk Management (QRM) tools described in ICH Q9 (Quality Risk Management). It provides a structured methodology for identifying possible equipment failures, evaluating their impact on product quality and determining appropriate mitigation measures before qualification and routine operation.

The Blister Packing Machine is one of the most critical pieces of equipment used in the Oral Solid Dosage (OSD) pharmaceutical manufacturing process. It is designed to automatically pack tablets or capsules into PVC/Aluminium (PVC–Alu) or Aluminium/Aluminium (Alu–Alu) blister packs by forming pockets, feeding products, sealing lidding foil, embossing or printing batch details, perforating, cutting and discharging finished blister packs.

The quality of blister-packed products directly depends upon the consistent performance of the Blister Packing Machine. Any malfunction may result in:

Incorrect product feeding
Missing tablets or capsules
Double feeding
Improper pocket formation
Improper sealing
Foil wrinkles
Leakage in blister packs
Incorrect batch coding
Poor print quality
Improper perforation
Incorrect cutting
Product contamination
Cross contamination
Product mix-up
Rejected blister packs
Equipment breakdown
Batch rejection

Therefore, a comprehensive Failure Mode and Effects Analysis (FMEA) is essential to identify all GMP-critical risks associated with the design, installation, operation, cleaning, maintenance and qualification of the Blister Packing Machine.

This Risk Assessment forms the basis for Design Qualification (DQ), Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ), ensuring that all GMP requirements are adequately addressed prior to routine pharmaceutical manufacturing.

OBJECTIVE OF RISK ASSESSMENT

The objective of this Risk Assessment is to identify and evaluate all potential failure modes associated with the Blister Packing Machine that may adversely affect:

Product Quality
Patient Safety
Equipment Performance
Process Consistency
Regulatory Compliance
Operator Safety
Environmental Protection

The specific objectives are:

To identify all GMP-critical equipment components.
To evaluate potential failure modes during installation, operation and cleaning.
To determine the likelihood and impact of each identified failure.
To establish suitable mitigation measures.
To ensure compliance with WHO GMP, EU GMP, PIC/S GMP and ICH Q9.
To verify that adequate engineering controls are incorporated into the equipment design.
To ensure that all critical GMP requirements are verified during IQ, OQ and PQ.
To minimize product contamination and cross-contamination.
To ensure operator safety during routine production.
To establish documented evidence supporting equipment qualification.

The outcome of this assessment will provide documented evidence that all foreseeable risks have been adequately identified and controlled before commercial pharmaceutical packaging.

Key Parameter of the Below Page:

FAILURE MODE EFFECT ANALYSIS FOR BLISTER PACKING MACHINE